Last reviewed · How we verify
Sumatriptan-naproxen combination
At a glance
| Generic name | Sumatriptan-naproxen combination |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- i-NEED: NEw migrainE Drugs Database
- Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study
- Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
- TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine (PHASE3)
- A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses. (PHASE1)
- Treximet ™ Pharmacy Budget Impact Model Database Validation Study
- Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents (PHASE3)
- A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sumatriptan-naproxen combination CI brief — competitive landscape report
- Sumatriptan-naproxen combination updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI